ArticleActa ophthalmologica2025

Faricimab versus bevacizumab for neovascular age-related macular degeneration: Cost analysis based on real-world data from the Swedish Macula Registry.

Souad Abdalla et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.